Clinical Research Directory
Browse clinical research sites, groups, and studies.
Compare the Efficacy and Safety of QL0605 Injections at Different Timepoints
Sponsor: Qilu Pharmaceutical Co., Ltd.
Summary
The goal of this real-world study is to compare the efficacy and safety of QL0605 administered 24 hours and 48 hours after chemotherapy in breast cancer patients.
Official title: A Randomized, Open-label, Interventional, Real-world Study to Compare the Efficacy and Safety of QL0605 Administered at Different Timepoints After Chemotherapy.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
336
Start Date
2024-09-19
Completion Date
2025-12-30
Last Updated
2024-09-27
Healthy Volunteers
No
Conditions
Interventions
QL0605(PEG-rhG-CSF)
Eligible patients are scheduled to receive 2 cycles of chemotherapy every three weeks. During each chemotherapy cycle QL0605 is injected 24 hours s.c. post chemotherapy application.
QL0605(PEG-rhG-CSF)
Eligible patients are scheduled to receive 2 cycles of chemotherapy every three weeks. During each chemotherapy cycle QL0605 is injected 48 hours s.c. post chemotherapy application.
Locations (1)
Shandong Cancer Hospital
Jinan, Shandong, China